Le Lézard
Classified in: Health, Science and technology
Subjects: AWD, TRI, FVT

Oncotarget awards grants to four biomedical researchers at Frontiers in Cancer Science

ORCHARD PARK, N.Y., Dec. 7, 2017 /PRNewswire/ -- Oncotarget, the world's largest oncology peer-reviewed research publication, awarded travel grants enabling four biomedical researchers to attend November's Frontiers in Cancer Science 2017 (FCS 2017) conference in Singapore. The travel sponsorship encourages the discussion of cancer discoveries in support of Oncotarget's commitment to maximizing the circulation of scientific research.

"We're dedicated to the wide dissemination of scientific advances to improve understanding and spur future discoveries," said Mikhail Blagosklonny, Oncotarget's editor-in-chief. "The Frontiers in Cancer Science meeting brings together top cancer experts from around the globe and as travel sponsor, Oncotarget is proud to have provided the opportunity for new and groundbreaking research from four international institutions to be shared at the meeting."

The sponsored researchers presented studies ranging from assessing the impact of drug treatments on kidney cancer to characterizing the chemoresistance of asbestos-related tumors.  The researchers and their presentations are as follows:

The FCS 2017 conference, which was held November 6 ? 8th, was hosted by seven major research institutes: Cancer Science Institute of Singapore, Duke-NUS Medical School, Genome Institute of Singapore, Institute of Molecular and Cell Biology and Lee Kong Chian School of Medicine.

For more biomedical research in oncology and related areas such as immunology and microbiology, the latest issue of Oncotarget is available at http://www.impactjournals.com/oncotarget.

About Oncotarget

Oncotarget is a twice-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology such as Aging, Immunology and Microbiology, Autophagy, Pathology and Chromosomes and more. Oncotarget is published by Rapamycin Press, the publishing division of Impact Journals LLC.

Media Contact Information:

Ryan James Jessup
Rapamycin Press


SOURCE Oncotarget

These press releases may also interest you

at 11:30
Efficacy and Tolerability Results With Oncofid®P-B in Patients With Papillary Bladder Cancer No new drug treatments for primary or recurrent papillary bladder cancer in 15 years Oncofid®P-B is a Paclitaxel-Hyaluronan Bioconjugate developed and...

at 09:49
MedyMatch Technology, a company focused on assisting physicians provide accurate patient assessment through artificial intelligence-based insights, (which recently received FDA Breakthrough Designation for its intracranial hemorrhage (ICH) detection...

at 05:03
Zhiliangzhi Siheyuan hosts the press conference for the Internet + Zhiliangzhi (Wuzhen) Conference. The Internet is gradually crossing technical restriction, from the age of big data and the era of cloud computing to the quantum computing age. The...

at 05:00
Tencent Video today announced its paid subscriptions reached 62.59 million as of the end of February 2018, which further enhanced its leading position as the largest online video platform in China. This demonstrated the platform's rapid growth...

at 04:01
On March 18, Hangzhou Hemos Lighting Company Limited (Hemos Lighting) showed its light bulbs, ceiling lights, panel lights, light strips and other products at the Frankfurt Light + Building Exhibition in Germany , making a leap in marching into the...

at 04:00
In cooperation with its partners, Tuya Smart participated in Light + Building in Frankfurt, Germany on March 18th, 2018. Known as the barometer of the lighting industry, Light + Building is one of the world's leading trade fairs for the lighting...

News published on 7 december 2017 at 14:36 and distributed by: